David Amsellem
Stock Analyst at Piper Sandler
(4.10)
# 562
Out of 4,732 analysts
143
Total ratings
54.62%
Success rate
11.08%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical | Maintains: Overweight | $23 → $30 | $21.92 | +36.86% | 10 | Jan 17, 2025 | |
| ITCI Intra-Cellular Therapies | Downgrades: Neutral | $107 → $132 | $126.20 | +4.60% | 1 | Jan 14, 2025 | |
| AVDL Avadel Pharmaceuticals | Maintains: Overweight | $24 → $13 | $7.75 | +67.74% | 5 | Jan 10, 2025 | |
| SAGE Sage Therapeutics | Maintains: Overweight | $26 → $9 | $7.08 | +27.12% | 1 | Jan 2, 2025 | |
| AMGN Amgen | Maintains: Overweight | $344 → $310 | $272.11 | +13.92% | 1 | Jan 2, 2025 | |
| NBIX Neurocrine Biosciences | Reiterates: Overweight | $160 | $143.26 | +11.69% | 9 | Dec 23, 2024 | |
| JAZZ Jazz Pharmaceuticals | Reiterates: Overweight | $163 | $121.18 | +34.51% | 12 | Dec 12, 2024 | |
| VTRS Viatris | Reiterates: Neutral | $13 → $14 | $11.30 | +23.89% | 6 | Dec 6, 2024 | |
| OPTN OptiNose | Maintains: Overweight | $45 → $15 | $6.38 | +135.11% | 2 | Nov 13, 2024 | |
| AMRX Amneal Pharmaceuticals | Maintains: Overweight | $9 → $11 | $8.26 | +33.17% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $3 | $3.20 | -6.25% | 4 | Nov 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $38 → $37 | $29.47 | +25.55% | 7 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $15 → $16 | $11.65 | +37.34% | 4 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $37 | $33.35 | +10.94% | 6 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $58.46 | +16.32% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $38 → $67 | $55.31 | +21.14% | 5 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $41 → $36 | $37.74 | -4.61% | 15 | Sep 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $11 → $6 | $3.68 | +63.04% | 9 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $71 → $66 | $35.70 | +84.87% | 6 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $7.44 | -59.68% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $22.36 | +87.84% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 → $24 | $15.74 | +52.48% | 5 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $10 | $3.10 | +222.58% | 1 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $3.66 | +473.77% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $91.94 | +22.91% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $144 → $12 | $4.65 | +158.06% | 3 | Nov 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $39.05 | +7.55% | 3 | Oct 16, 2023 |
Teva Pharmaceutical
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $21.92
Upside: +36.86%
Intra-Cellular Therapies
Jan 14, 2025
Downgrades: Neutral
Price Target: $107 → $132
Current: $126.20
Upside: +4.60%
Avadel Pharmaceuticals
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $7.75
Upside: +67.74%
Sage Therapeutics
Jan 2, 2025
Maintains: Overweight
Price Target: $26 → $9
Current: $7.08
Upside: +27.12%
Amgen
Jan 2, 2025
Maintains: Overweight
Price Target: $344 → $310
Current: $272.11
Upside: +13.92%
Neurocrine Biosciences
Dec 23, 2024
Reiterates: Overweight
Price Target: $160
Current: $143.26
Upside: +11.69%
Jazz Pharmaceuticals
Dec 12, 2024
Reiterates: Overweight
Price Target: $163
Current: $121.18
Upside: +34.51%
Viatris
Dec 6, 2024
Reiterates: Neutral
Price Target: $13 → $14
Current: $11.30
Upside: +23.89%
OptiNose
Nov 13, 2024
Maintains: Overweight
Price Target: $45 → $15
Current: $6.38
Upside: +135.11%
Amneal Pharmaceuticals
Nov 11, 2024
Maintains: Overweight
Price Target: $9 → $11
Current: $8.26
Upside: +33.17%
Nov 11, 2024
Downgrades: Neutral
Price Target: $3
Current: $3.20
Upside: -6.25%
Oct 25, 2024
Reiterates: Overweight
Price Target: $38 → $37
Current: $29.47
Upside: +25.55%
Oct 25, 2024
Reiterates: Overweight
Price Target: $15 → $16
Current: $11.65
Upside: +37.34%
Oct 11, 2024
Reiterates: Neutral
Price Target: $37
Current: $33.35
Upside: +10.94%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $58.46
Upside: +16.32%
Sep 18, 2024
Maintains: Overweight
Price Target: $38 → $67
Current: $55.31
Upside: +21.14%
Sep 11, 2024
Downgrades: Neutral
Price Target: $41 → $36
Current: $37.74
Upside: -4.61%
Aug 9, 2024
Maintains: Overweight
Price Target: $11 → $6
Current: $3.68
Upside: +63.04%
Aug 8, 2024
Maintains: Overweight
Price Target: $71 → $66
Current: $35.70
Upside: +84.87%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $7.44
Upside: -59.68%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $22.36
Upside: +87.84%
Apr 29, 2024
Maintains: Overweight
Price Target: $22 → $24
Current: $15.74
Upside: +52.48%
Apr 11, 2024
Initiates: Overweight
Price Target: $10
Current: $3.10
Upside: +222.58%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $3.66
Upside: +473.77%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $91.94
Upside: +22.91%
Nov 14, 2023
Downgrades: Neutral
Price Target: $144 → $12
Current: $4.65
Upside: +158.06%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $39.05
Upside: +7.55%